Porcia T Bradford1, D Michal Freedman, Alisa M Goldstein, Margaret A Tucker. 1. Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, 6120 Executive Boulevard, Rockville, MD 20852, USA. bradfordp@mail.nih.gov
Abstract
OBJECTIVE: To quantify the risk of subsequent primary cancers among patients with primary cutaneous malignant melanoma. DESIGN: Population-based registry study. SETTING: We evaluated data from 9 cancer registries of the Surveillance, Epidemiology, and End Results program from 1973-2006. PARTICIPANTS: We included 89 515 patients who survived at least 2 months after their initial melanoma diagnosis. RESULTS: Of the patients with melanoma, 10 857 (12.1%) developed 1 or more subsequent primary cancers. The overall risk of a subsequent primary cancer increased by 28% (observed to expected [O:E] ratio = 1.28). One quarter of the cancers were subsequent primary melanomas (O:E = 8.61). Women with head and neck melanoma and patients younger than 30 had markedly increased risks (O:E = 13.22 and 13.40, respectively) of developing a subsequent melanoma. Second melanomas were more likely to be thin than were the first of multiple primary melanomas (thickness at diagnosis <1.00 mm, 77.9% vs 70.3%, respectively; P < .001). Melanoma survivors had increased risk of developing several cancers; the most common cancers with elevated risks were breast, prostate, and non-Hodgkin lymphoma (O:E = 1.10, 1.15, and 1.25, respectively). CONCLUSIONS: Melanoma survivors have an approximately 9-fold increased risk of developing subsequent melanoma compared with the general population. The risk remains elevated more than 20 years after the initial melanoma diagnosis. This increased risk may be owing to behavioral factors, genetic susceptibility, or medical surveillance. Although the percentage of subsequent primary melanomas thicker than 1 mm is lower than for the first of multiple primary melanomas, it is still substantial. Melanoma survivors should remain under surveillance not only for recurrence but also for future primary melanomas and other cancers.
OBJECTIVE: To quantify the risk of subsequent primary cancers among patients with primary cutaneous malignant melanoma. DESIGN: Population-based registry study. SETTING: We evaluated data from 9 cancer registries of the Surveillance, Epidemiology, and End Results program from 1973-2006. PARTICIPANTS: We included 89 515 patients who survived at least 2 months after their initial melanoma diagnosis. RESULTS: Of the patients with melanoma, 10 857 (12.1%) developed 1 or more subsequent primary cancers. The overall risk of a subsequent primary cancer increased by 28% (observed to expected [O:E] ratio = 1.28). One quarter of the cancers were subsequent primary melanomas (O:E = 8.61). Women with head and neck melanoma and patients younger than 30 had markedly increased risks (O:E = 13.22 and 13.40, respectively) of developing a subsequent melanoma. Second melanomas were more likely to be thin than were the first of multiple primary melanomas (thickness at diagnosis <1.00 mm, 77.9% vs 70.3%, respectively; P < .001). Melanoma survivors had increased risk of developing several cancers; the most common cancers with elevated risks were breast, prostate, and non-Hodgkin lymphoma (O:E = 1.10, 1.15, and 1.25, respectively). CONCLUSIONS:Melanoma survivors have an approximately 9-fold increased risk of developing subsequent melanoma compared with the general population. The risk remains elevated more than 20 years after the initial melanoma diagnosis. This increased risk may be owing to behavioral factors, genetic susceptibility, or medical surveillance. Although the percentage of subsequent primary melanomas thicker than 1 mm is lower than for the first of multiple primary melanomas, it is still substantial. Melanoma survivors should remain under surveillance not only for recurrence but also for future primary melanomas and other cancers.
Authors: Sara Gandini; Francesco Sera; Maria Sofia Cattaruzza; Paolo Pasquini; Damiano Abeni; Peter Boyle; Carmelo Francesco Melchi Journal: Eur J Cancer Date: 2005-01 Impact factor: 9.162
Authors: Alisa M Goldstein; Maria Teresa Landi; Shirley Tsang; Mary C Fraser; David J Munroe; Margaret A Tucker Journal: Cancer Epidemiol Biomarkers Prev Date: 2005-09 Impact factor: 4.254
Authors: Vinayak K Nahar; M Allison Ford; Robert T Brodell; Javier F Boyas; Stephanie K Jacks; Rizwana Biviji-Sharma; Mary A Haskins; Martha A Bass Journal: J Cancer Res Clin Oncol Date: 2015-12-07 Impact factor: 4.553
Authors: Megan M Herr; Sara J Schonfeld; Graça M Dores; Diana R Withrow; Margaret A Tucker; Rochelle E Curtis; Lindsay M Morton Journal: J Natl Cancer Inst Date: 2018-11-01 Impact factor: 13.506
Authors: Sara J Schonfeld; Diana M Merino; Rochelle E Curtis; Amy Berrington de González; Megan M Herr; Ruth A Kleinerman; Sharon A Savage; Margaret A Tucker; Lindsay M Morton Journal: JNCI Cancer Spectr Date: 2019-06-20
Authors: Nadine A Kasparian; Shab Mireskandari; Phyllis N Butow; Mbathio Dieng; Anne E Cust; Bettina Meiser; Kristine Barlow-Stewart; Scott Menzies; Graham J Mann Journal: Support Care Cancer Date: 2016-07-27 Impact factor: 3.603
Authors: June K Robinson; Jeffrey D Wayne; Mary C Martini; Brittney A Hultgren; Kimberly A Mallett; Rob Turrisi Journal: JAMA Dermatol Date: 2016-09-01 Impact factor: 10.282